TP53 and acute myeloid leukemia: DDR + venetoclax doublets re-sensitized venetoclax-refractory AML, consistent with mitochondrial re-priming, with a 2025 phase I study showing a 40% CR rate in TP53-mutant AML (Schüpbach et al., 2025).